How Community Health Centers Protect 340B Savings When HRSA Comes Knocking

28 Jul How Community Health Centers Protect 340B Savings When HRSA Comes Knocking

The 340B drug pricing program delivers substantial savings to covered entities serving underserved patient populations. Savings that directly fund care for the patients who need it most. But those savings only stay protected when the compliance infrastructure around the program is built to withstand HRSA scrutiny. That gap between generating savings and being able to defend them is where audit exposure lives.

Key Takeaways

• The 340B program requires ongoing compliance infrastructure, not just enrollment paperwork, to protect savings from audit risk.
• The most common audit findings trace back to diffused accountability. No single role owns compliance in full, so gaps accumulate undetected.
• Larger programs carry more compliance surface area, not less. Scale without updated infrastructure creates concentrated risk per dollar saved.
• Clean audit history reflects past performance under past criteria, not current program integrity under current HRSA methodology.
• Starting compliance work before an audit notice arrives is consistently where the highest return on consulting investment is found.

What Does a 340B Compliance Failure Actually Look Like Before Anyone Notices?

The savings are real. The compliance gaps that accumulate alongside them are just as real. They’re just quieter.

Consider a typical community health center that enrolled in the 340B program several years ago. Implementation went smoothly, drug costs dropped, and program management got folded into existing pharmacy and administrative workflows. Distributed across staff who each owned a piece of it, but nobody owned in full. The finance team was satisfied. Compliance felt handled.

Then HRSA scheduled an audit.

What surfaced wasn’t fraud. It wasn’t intentional misuse. It was documentation drift: patient eligibility records that didn’t consistently tie back to the covered entity’s patient definition, contract pharmacy oversight that hadn’t been updated as the program grew, and split-billing logs that reflected how things had actually been running rather than how the program required them to run. Every dispensing was likely appropriate. The problem was that the documentation couldn’t prove it.

That’s the structural problem at the center of most audit findings. It’s not bad intent. It’s a compliance architecture that was never designed to carry the weight of a mature, scaled 340B program.

Why Do Well-Run Organizations Still Accumulate Audit Risk?

There are two dynamics that make this harder than it looks.

First, the program’s administrative requirements are genuinely complex. Covered entities must maintain compliance across patient eligibility, diversion prevention, duplicate discount avoidance, contract pharmacy arrangements, and child site registration. Simultaneously, across every qualifying encounter. That’s not a single workflow. It’s a documentation architecture spread across multiple departments, each with its own priorities.

Second, HRSA’s audit methodology has grown more precise over time. According to HRSA’s published audit protocols, auditors assess whether covered entities can produce contemporaneous evidence of compliance. Not just policies, but records. What passed review several years ago may not meet current evidentiary standards. Organizations that haven’t revisited their documentation practices relative to current HRSA criteria are making assumptions they haven’t tested.

A useful way to map this exposure is through what practitioners in the field describe as a four-zone compliance assessment framework:

• Zone 1. Enrollment Accuracy: Is the entity’s registration current and correctly reflecting all eligible sites and patient populations?
• Zone 2. Eligibility Documentation: Can the organization demonstrate, for any given dispensing, that the patient met the covered entity’s patient definition at the time of the encounter?
• Zone 3. Diversion and Duplicate Discount Controls: Are split-billing systems and contract pharmacy arrangements being actively monitored, or just configured and left?
• Zone 4. Audit Readiness: Is documentation organized to HRSA’s evidentiary standards. Not just internal standards that feel logical but may not hold up under review?

Most organizations that receive audit findings have gaps in Zone 3 or Zone 4. They’re not doing anything wrong in real time. They just can’t prove they weren’t.

Understanding what HRSA auditors are actually looking for before an audit begins is the preparation work that consistently produces the strongest audit outcomes.

The Counterintuitive Problem With a Larger Program

Here’s an assumption worth examining directly: organizations with larger 340B programs are better positioned to manage compliance because they have more resources.

The opposite is usually true.

A larger program means more dispensing volume, more contract pharmacy relationships, more child sites, and more individual transactions that each need to be defensible under audit. The compliance surface area grows with the savings. Organizations that scaled their program without a corresponding update to compliance infrastructure are carrying more risk per dollar saved than a smaller, tightly managed program. Not less.

Scale without compliance infrastructure isn’t a success story. It’s a liability that hasn’t been tested yet.

The second assumption worth challenging: that an organization with no prior audit findings is in good shape. Prior finding-free status reflects what HRSA examined last time, under the methodology that applied then. It says nothing about the current state of the program or how it would perform against current audit criteria. Clean history is evidence of past compliance. It’s not a substitute for current program integrity.

What a Structured Consulting Engagement Actually Looks Like

Here’s what the process typically looks like in practice. Not as a guarantee, but as a representative engagement arc.

An organization contacts Ponaman Healthcare Consulting either after receiving an HRSA audit notice or, more advantageously, before one arrives. The first phase is an independent compliance review: a structured assessment of the program against current HRSA audit criteria. This isn’t a checkbox exercise. It’s designed to surface what an auditor would find, before they find it.

What these reviews consistently uncover falls into predictable categories: patient eligibility documentation that doesn’t fully satisfy the covered entity’s own patient definition, contract pharmacy oversight that hasn’t kept pace with program growth, and split-billing configurations that have drifted from program requirements. None of these are unusual. Most covered entities have at least one.

The second phase is remediation. Correcting gaps with documentation that will hold up under audit scrutiny is different from fixing the operational issue internally. Internal teams often solve the symptom. Expert consultants build the evidentiary record that defends the program.

If an audit is already in progress, the work shifts to audit response: organizing documentation, preparing responses to findings, and, when findings are issued, building the appeal. Most organizations that accept findings without appeal don’t realize how viable the appeal path actually is, or how much the outcome depends on the quality of the evidentiary argument rather than the nature of the finding itself.

A limitation worth naming honestly: no consulting engagement can retroactively fix documentation that was never created. When contemporaneous records don’t exist, the remediation options narrow. That’s one reason why ongoing compliance monitoring. As a continuous operational function rather than a pre-audit effort. Produces better outcomes than reactive engagement.

Managing This Internally vs. Working With Expert Support

The cost of the wrong choice isn’t the consulting fee. It’s program termination, repayment demands, and the loss of the drug pricing access that was funding care for patients with no alternative.

Who Gets the Most From This Kind of Support?

This matters most when the stakes are highest.

Organizations that benefit most from structured consulting support include those with active HRSA audits or recent findings, those that have scaled their program significantly without a corresponding compliance review, FQHCs and look-alikes facing their first HRSA audit, and hospitals managing complex contract pharmacy arrangements or multiple child sites. If your program has grown, if your documentation practices haven’t been reviewed against current HRSA criteria recently, or if an audit notice is already on your desk. The risk exposure is real and the window to act is narrower than it looks.

What this support isn’t built for: an organization that hasn’t yet qualified as a covered entity and is in early exploratory stages. For everyone else. Any organization generating real savings and carrying real compliance exposure. The question isn’t whether qualified support is worth it. It’s whether the current approach is actually protecting what the program has built.

The difference between strong and weak audit outcomes is almost never the program itself. It’s the infrastructure around it.

Frequently Asked Questions

How do I know if my 340B program is at risk before HRSA contacts us?

Most compliance gaps don’t announce themselves. They accumulate in documentation practices, contract pharmacy oversight, and patient eligibility records. An independent compliance review applied against current HRSA audit criteria is the only reliable way to understand your actual exposure before an auditor determines it for you.

What’s the difference between an internal compliance review and an external one?

An internal review reflects what your team knows to look for, using your own documentation standards. An external review applies the evidentiary criteria HRSA auditors actually use. Which are more specific and more demanding than most internal standards. The gap between those two is where most findings originate.

If we receive audit findings, is there any realistic path to overturning them?

Yes, and it’s more viable than most organizations realize. The appeal process rewards well-organized, thorough evidentiary responses. Many organizations that accept findings without appeal simply don’t know that path exists, or haven’t worked with consultants who know how to build an effective appeal argument.

How long does a compliance review typically take?

Timeline depends on program complexity, number of sites, and the state of existing documentation. A focused pre-audit review for a single-site FQHC looks different from a multi-site hospital system engagement. What’s consistent is that starting earlier creates more time to remediate before HRSA arrives.

What happens if HRSA finds a major violation?

HRSA can require repayment of overcharges, issue corrective action plans, or in serious cases terminate program participation. Termination means losing access to 340B pricing entirely. A direct reduction in the resources available for patient care. That’s the actual cost of unmanaged compliance risk.

We’ve never had an audit finding. Should we still invest in compliance support?

Clean audit history reflects past performance under past criteria. HRSA’s audit methodology has grown more precise, and program requirements have evolved. Organizations that haven’t reviewed their compliance practices against current expectations are operating on assumptions that may no longer hold. Past findings-free status is evidence of prior compliance, not current protection.

Does the 340B program’s administrative complexity justify the effort?

For covered entities serving underserved populations, the savings are substantial. Substantial enough that protecting them deserves the same operational seriousness the savings themselves receive. The administrative burden is real, but it’s manageable with the right infrastructure. The question isn’t whether the program is worth it. It’s whether your compliance infrastructure matches the savings you’re generating.

Your Program Generated Real Savings. Those Savings Deserve Real Protection.

The 340B drug pricing program works. For covered entities serving patients who depend on affordable care, it works significantly. What doesn’t work is treating enrollment as the finish line when it’s actually the starting point for the compliance work that keeps the program intact.

If you’re reading this after receiving an audit notice, the window for proactive remediation has closed. The window for expert audit response is still open. If you’re reading this before an audit, that window is exactly what you should be using.

Contact Ponaman Healthcare Consulting to schedule a compliance review and find out where your program actually stands. Before HRSA determines it for you.